Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Metformin – Forschungsarchiv – Seite 33 von 35 | SupStack

Metformin – Forschungsarchiv

Studien 2551–2600 von 2685, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

2551RCT2000

Palmer AJ, Sendi PP, Spinas GA · Schweiz Med Wochenschr (2000)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

2552RCT2000

Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH · J Clin Pharmacol (2000)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

2553RCT2000

Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S · JAMA (2000)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Metformin – Forschungsarchiv

Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.

Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food.

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.

Effect of altered gastric emptying and gastrointestinal motility on metformin absorption.

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.

Rosiglitazone does not alter the pharmacokinetics of metformin.

Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.

Side effects. Metformin for blood sugar problems.

In-vitro in-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers.

The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

Encouraging Metformin data reported by researchers.

Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.

Effects of antihyperglycaemic therapies on proinsulin and relation between proinsulin and cardiovascular risk factors in type 2 diabetes.

Metformin and contrast media--a dangerous combination?

Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin.

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

Efficacy of metformin in the treatment of NIDDM. Meta-analysis.

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.

Addition of benfluorex to biguanide improves glycemic control in obese non-insulin-dependent diabetes: a double-blind study versus placebo.

Repaglinide in combination therapy with metformin in Type 2 diabetes.

Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy.

Pharmacokinetics of the antihyperglycemic agent metformin in cats.

Relating in vitro/in vivo data of two controlled-release metformin formulations.

[Metformin in the UKPDS study. Metabolic and vascular results].

Effect of metformin on patients with impaired glucose tolerance.

Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity.

Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes.

A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.

Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance.

Metformin added to insulin therapy in poorly controlled type 2 diabetes.

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

[Controversial aspects regarding metformin in type 2 diabetic patient: reduction of late complications in early, single drug administration; increased risk of death in later administration in combination with sulfonylurea compounds].

Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.

Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus.

Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes.

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment.

Comparison of bedtime NPH insulin or metformin combined with glibenclamide in secondary sulphonylurea failure in obese type II (NIDDM) patients.

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity.